Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Century Therapeutics (IPSC) Research & Development (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Research & Development for 4 consecutive years, with $19.7 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 32.95% to $19.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $95.7 million through Dec 2025, down 10.8% year-over-year, with the annual reading at $95.7 million for FY2025, 10.8% down from the prior year.
  • Research & Development for Q4 2025 was $19.7 million at Century Therapeutics, down from $22.5 million in the prior quarter.
  • The five-year high for Research & Development was $29.4 million in Q4 2024, with the low at $19.7 million in Q4 2025.
  • Average Research & Development over 4 years is $24.5 million, with a median of $24.7 million recorded in 2022.
  • The sharpest move saw Research & Development surged 31.75% in 2024, then tumbled 32.95% in 2025.
  • Over 4 years, Research & Development stood at $25.6 million in 2022, then dropped by 12.86% to $22.3 million in 2023, then soared by 31.75% to $29.4 million in 2024, then crashed by 32.95% to $19.7 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $19.7 million, $22.5 million, and $26.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.